Compare CBL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBL | PHAR |
|---|---|---|
| Founded | 1978 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1995 | 2020 |
| Metric | CBL | PHAR |
|---|---|---|
| Price | $48.00 | $13.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $45.00 | $38.33 |
| AVG Volume (30 Days) | ★ 213.3K | 12.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 132.09 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $578,373,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $32.71 | $3,041.22 |
| Revenue Growth | ★ 12.18 | N/A |
| 52 Week Low | $24.33 | $9.54 |
| 52 Week High | $49.18 | $21.34 |
| Indicator | CBL | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 65.24 | 40.26 |
| Support Level | $36.41 | $12.98 |
| Resistance Level | $48.64 | $13.44 |
| Average True Range (ATR) | 1.45 | 0.45 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 71.58 | 65.80 |
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.